Solvay Pharmaceuticals has renewed its clinical development alliance with Quintiles Transnational Corp. for another five years. First signed in 2001, the renewal reflects the success in accelerating development of Solvay's product portfolio and improving efficiency.
Through the alliance, Solvay has completed three Phase III programs, moved two compounds from Phase II to Phase III earlier than expected, and produced conclusive Phase II data that resulted in the termination of two other programs, freeing Resources for other development work.
"Using Quintiles' global infrastructure and experts as a strategic asset, we've advanced projects at a much faster rate than we could have achieved alone, and with greater flexibility," said Werner Cautreels, chief executive officer of Solvay Pharmaceuticals. "Over the next five years we aim to achieve even higher levels of value in terms of efficiency, speed and cost-savings."
Quintiles chairman and chief executive officer, Dennis Gillings, Ph.D., CBE, said, "This alliance shows the power of strategic partnering to create a more efficient and flexible drug development platform. Both Solvay and Quintiles are focused on a single goal -- moving products efficiently through development and on to patients in need. This renewal demonstrates the progress we've made and our shared passion to achieve that goal."